Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03709420
Recruitment Status : Recruiting
First Posted : October 17, 2018
Last Update Posted : August 9, 2019
Sponsor:
Collaborator:
Richmond Pharmacology Limited
Information provided by (Responsible Party):
Forendo Pharma Ltd

Tracking Information
First Submitted Date  ICMJE October 8, 2018
First Posted Date  ICMJE October 17, 2018
Last Update Posted Date August 9, 2019
Actual Study Start Date  ICMJE August 13, 2018
Estimated Primary Completion Date November 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 7, 2019)
  • Safety and tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs). [ Time Frame: Throughout the study until the follow-up visit, i.e. 7 days after the last dose in Parts I and II and until day 35 in Part III. ]
    All adverse events will be assessed by the investigator and graded for severity according to the criteria from National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v4.03.
  • Proportion of subjects with clinically significant changes in laboratory safety tests. [ Time Frame: Throughout the study until the follow-up visit, i.e. 7 days after the last dose in Parts I and II and until day 35 in Part III. ]
    Laboratory safety tests include haematology, chemistry, coagulation and urinalysis.
  • Proportion of subjects with changes in vital signs (blood pressure, diastolic blood pressure and pulse) [ Time Frame: Throughout the study until the follow-up visit, i.e. 7 days after the last dose in Parts I and II and until day 35 in Part III. ]
    Vital signs will be measures using automated monitors in supine position after 5 minute rest.
  • Proportion of subjects with ECG changes. [ Time Frame: Throughout the study until the follow-up visit, i.e. 7 days after the last dose in Parts I and II and until day 35 in Part III. ]
    12-lead ECGs and ECG telemetry (only Parts I and II) will be used to measure ECG parameters.
  • Presence of any pathology in transvaginal ultrasound (Part III). [ Time Frame: Throughout the study until the day of the last dose (day 14). ]
    Transvaginal ultrasound will be performed at multiple timepoints.
Original Primary Outcome Measures  ICMJE
 (submitted: October 12, 2018)
  • Safety and tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs). [ Time Frame: Throughout the study up to 7 days after the last dose. ]
    All adverse events will be assessed by the investigator and graded for severity according to the criteria from National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v4.03.
  • Proportion of subjects with clinically significant changes in laboratory safety tests. [ Time Frame: Throughout the study up to 7 days after the last dose. ]
    Laboratory safety tests include haematology, chemistry, coagulation and urinalysis.
  • Proportion of subjects with changes in vital signs (blood pressure, diastolic blood pressure and pulse) [ Time Frame: Throughout the study up to 7 days after the last dose. ]
    Vital signs will be measures using automated monitors in supine position after 5 minute rest.
  • Proportion of subjects with ECG changes. [ Time Frame: Throughout the study up to 7 days after the last dose. ]
    12-lead ECGs and ECG telemetry will be used to measure ECG parameters.
Change History Complete list of historical versions of study NCT03709420 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 7, 2019)
  • Maximum observed plasma concentration (Cmax). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose after the single dose (SAD) and up to 72 hours after the last dose (Parts II and III). ]
  • Area under the plasma concentration-time curve (AUC). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose after the single dose (SAD) and up to 72 hours after the last dose (Parts II and III). ]
  • Time to maximum plasma concentration (Cmax). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose after the single dose (SAD) and up to 72 hours after the last dose (Parts II and III). ]
  • Terminal half-life (t½). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose after the single dose (SAD) and up to 72 hours after the last dose (Parts II and III). ]
  • Effect of food on the pharmacokinetic profile of FOR-6219 and metabolite FOR-6287 based on maximum observed plasma concentration (Cmax) (Part II). [ Time Frame: Predose and multiple timepoints post-dose in fed (Day 1) and fasted conditions (Days 3-10). ]
  • Effect of food on the pharmacokinetic profile of FOR-6219 and metabolite FOR-6287 based on area under the plasma concentration-time curve (AUC) (Part II). [ Time Frame: Predose and multiple timepoints post-dose in fed (Day 1) and fasted conditions (Days 3-10). ]
  • Change in systemic hormone levels (Part III). [ Time Frame: Days 1, 3, 5, 7, 10, 12 and 14. ]
    Systemic hormones include oestradiol (E2), estrone (E1), luteinizing hormone (LH), follicle stimulating hormone (FSH) and progesterone.
  • Change in endometrial thickness (Part III). [ Time Frame: Days 3, 7, 10 and 14. ]
    Endometrial thickness will be measured by transvaginal ultrasound.
  • Change in follicle volume (Part III). [ Time Frame: Days 3, 7, 10 and 14. ]
    Follicle volume will be measured by transvaginal ultrasound.
Original Secondary Outcome Measures  ICMJE
 (submitted: October 12, 2018)
  • Maximum observed plasma concentration (Cmax). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose up to 72 hours after the single dose (SAD) and after the last dose (MAD) ]
  • Area under the plasma concentration-time curve (AUC). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose up to 72 hours after the single dose (SAD) and after the last dose (MAD) ]
  • Time to maximum plasma concentration (Cmax). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose up to 72 hours after the single dose (SAD) and after the last dose (MAD) ]
  • Terminal half-life (t½). [ Time Frame: Pharmacokinetic measures will be taken predose and multiple timepoints postdose up to 72 hours after the single dose (SAD) and after the last dose (MAD) ]
  • Effect of food on the pharmacokinetic profile of FOR-6219 and metabolite FOR-6287 based on maximum observed plasma concentration (Cmax). [ Time Frame: Predose and multiple timepoints post-dose in fed (Day 1) and fasted conditions (Days 3-10) in Part II (MAD) ]
  • Effect of food on the pharmacokinetic profile of FOR-6219 and metabolite FOR-6287 based on area under the plasma concentration-time curve (AUC). [ Time Frame: Predose and multiple timepoints post-dose in fed (Day 1) and fasted conditions (Days 3-10) in Part II (MAD) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219
Official Title  ICMJE A Phase I/Ib, Randomised, Double-blind, Placebo-controlled Study in Healthy Postmenopausal and Pre-menopausal Women to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics of Single and Multiple Ascending Oral Doses of FOR-6219 and the Pharmacodynamics of Multiple Oral Doses of FOR-6219
Brief Summary This is a randomised, double-blind, placebo-controlled, Phase I/Ib study which will assess the safety, tolerability, food effect, pharmacokinetics and pharmacodynamics of FOR-6219, a hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor. The study will be performed in three parts: (I) Single ascending doses (SAD) in healthy post-menopausal women; (II) multiple ascending doses (MAD) in post-menopausal women; (III) multiple ascending doses in healthy pre-menopausal women.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Endometriosis
Intervention  ICMJE
  • Drug: Placebo
    Placebo capsule to match active drug
  • Drug: FOR-6219
    FOR-6219 capsule
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Matching placebo capsule
    Intervention: Drug: Placebo
  • Experimental: FOR-6219

    Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.

    Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.

    Part III: Multiple oral doses of 10 mg, 25 mg and 75 mg BID

    Intervention: Drug: FOR-6219
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 7, 2019)
72
Original Estimated Enrollment  ICMJE
 (submitted: October 12, 2018)
36
Estimated Study Completion Date  ICMJE November 30, 2019
Estimated Primary Completion Date November 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

PART I and II (postmenopausal women):

Inclusion Criteria:

  • Healthy Caucasian female volunteers between 45 and 65 years (inclusive) at screening.
  • Female volunteers must be either naturally (spontaneously) post-menopausal: Natural (spontaneous) postmenopause is defined as being amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25.8 IU/L and 17β-oestradiol serum levels less than 183 pmol/L (or the local laboratory levels for post-menopause) OR must have had a bilateral oophorectomy/bilateral salpingo-oophorectomy. Hysterectomised women can be included only if they have had bilateral oophorectomy.
  • Volunteers not taking hormone replacement therapy (HRT).
  • Has a body weight between 50kg and 100kg inclusive and a body mass index (BMI) between 18.0-32.0 kg/m^2 inclusive.
  • Satisfactory medical assessment with no clinically significant or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory evaluation (haematology, biochemistry, coagulation and urinalysis) that is reasonably likely to interfere with the volunteer's participation in or ability to complete the study as assessed by the investigator.
  • Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures.
  • Ability to swallow multiple capsules at a time or (consecutively) one capsule at a time.
  • An understanding, ability, and willingness to fully comply with study procedures and restrictions.

Exclusion Criteria:

  • Post-menopausal women with less than 12 months amenorrhoea or women with amenorrhoea due to other medical causes.
  • Current or recurrent disease (e.g., cardiovascular, haematological, neurological, endocrine, immunological, renal, hepatic or gastrointestinal or other conditions) that could affect the action, absorption, or disposition of FOR-6219, or could affect clinical assessments or clinical laboratory evaluations.
  • Current or relevant history of physical or psychiatric illness that are not stable or may require a change in treatment, use of prohibited therapies during the study or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study may influence the result of the study, or the subject's ability to participate in the study.
  • The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long QT syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events.
  • Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of corrected QT (QTc) interval changes.
  • Has vital signs consistently outside of the following normal range. Supine blood pressure (after at least 5 minutes of supine rest):

    • Systolic blood pressure: 90 - 145 mmHg.
    • Diastolic blood pressure: 40 - 95 mmHg.
  • Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
  • Evidence of pregnancy.
  • Any other abnormal findings on vital signs, ECG, physical examination or laboratory evaluation of blood and urine samples that the Investigator judges as likely to interfere with the study or pose an additional risk in participating.
  • Positive test results for alcohol or drugs of abuse.
  • History or clinical evidence of substance and/or alcohol abuse within the two years before screening.
  • Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within three months prior to the planned first day of dosing.
  • Has used any medication that is either an inhibitor or inducer of CYP3A4 within 28 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing. Additionally, subjects must not have consumed other substances known to be potent inhibitors or inducers of cytochrome P450 (CYP P450s) in the two weeks before the planned first study drug administration.
  • Has used any other prescription or over-the-counter medication (including herbal or homeopathic preparations; excluding vitamin/mineral supplements and occasional paracetamol) within 14 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing that the Investigator judges is likely to interfere with the study or pose an additional risk in participating.
  • Consumption of herbal remedies or dietary supplements containing St. John's Wort in the 3 weeks before the planned Day 1 of the dosing period.
  • Has received an investigational product or been treated with an investigational device within 90 days prior to first drug administration and will not start any other investigational product or device study within 90 days after last study drug administration.
  • Known or suspected intolerance or hypersensitivity to the investigational product, any closely related compound, or any of the stated ingredients.
  • History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
  • Has donated or lost 400 mL blood or more within the last 16 weeks preceding the first day of dosing.
  • Has a mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study requirements.
  • An inability to follow a standardised diet and meal schedule or inability to fast, as required during the study.
  • Prior screen failure (where the cause of the screen failure is not deemed to be temporary), randomisation, participation, or enrolment in this study. Subjects who initially failed due to temporary non-medically significant issues are eligible for rescreening once the cause has resolved.

PART III (premenopausal women):

Inclusion Criteria:

  • Healthy female volunteers between age 18-39 years (inclusive) at screening and not planning pregnancy during the month following the study completion.
  • The subject is premenopausal with a regular ovulatory menstrual cycle with an interval of 26-31 days based on medical history during the past 3 months and as confirmed by the control menstrual cycle prior to dosing.
  • Volunteers not taking oral contraceptives.
  • Has a body weight between 45kg and 90kg inclusive and a body mass index (BMI between 18.0-30.0 kg/m^2 inclusive).
  • Satisfactory medical assessment with no clinically significant or relevant abnormalities as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluation (haematology, biochemistry, coagulation and urinalysis) that is reasonably likely to interfere with the volunteer's participation in or ability to complete the study as assessed by the investigator.
  • Satisfactory medical assessment with no clinically significant or relevant abnormalities as determined by gynaecological examination and transvaginal ultrasound (TVUS), that would interfere with the assessment of the endometrial thickness or endometrial biopsy.
  • Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable regulations, before completing any study-related procedures.
  • Ability to swallow multiple capsules at a time or (consecutively) one capsule at a time.
  • An understanding, ability, and willingness to fully comply with study procedures and restrictions.
  • The subjects must agree to use the study-specific contraceptive methods from screening up to 30 days after the follow-up visit.

Exclusion Criteria:

  • Post-menopausal women, defined as with more than 12 months amenorrhoea.
  • Current or recurrent disease (e.g., cardiovascular, haematological, neurological, endocrine, immunological, renal, hepatic or gastrointestinal or other conditions) that could affect the action, absorption, or disposition of FOR-6219, or could affect clinical assessments or clinical laboratory evaluations.
  • Current or recurrent gynaecological disease that could affect the clinical assessments.
  • Current or relevant history of physical or psychiatric illness that are not stable or may require a change in treatment, use of prohibited therapies during the study or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study may influence the result of the study, or the subject's ability to participate in the study.
  • The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long QT syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events.
  • Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG or clinically important abnormalities that may interfere with the interpretation of QTc interval changes.
  • Has vital signs consistently outside of the following normal range. Supine blood pressure (after at least 5 minutes of supine rest):

    • Systolic blood pressure: 90 - 140 mmHg.
    • Diastolic blood pressure: 40 - 90 mmHg.
  • Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
  • Evidence of pregnancy
  • Any other abnormal findings on vital signs, ECG, physical examination or laboratory evaluation of blood and urine samples that the Investigator judges as likely to interfere with the study or pose an additional risk in participating.
  • Positive test results for alcohol or drugs of abuse.
  • History or clinical evidence of substance and/or alcohol abuse within the two years before screening.
  • Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within three months prior to the planned first day of dosing.
  • Has used any medication that is either an inhibitor or inducer of CYP3A4 within 28 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing. Additionally, subjects must not have consumed other substances known to be potent inhibitors or inducers of cytochrome P450 (CYP P450s) in the two weeks before the planned first study drug administration.
  • Has used any other prescription or over-the-counter medication (including herbal or homeopathic preparations; excluding vitamin/mineral supplements, measures for pain relief during biopsy (such as use of local anaesthetic and/or NSAIDs) and occasional paracetamol) within 14 days or 10 half-lives (whichever is longer) prior to the planned first day of dosing that the Investigator judges is likely to interfere with the study or pose an additional risk in participating.
  • Consumption of herbal remedies or dietary supplements containing St. John's Wort in the 3 weeks before the planned Day 1 of the dosing period.
  • Use of oral contraceptives, contraceptive intrauterine device, or any other hormonal medication that may have an impact on the hormonal levels, assessment of endometrium or follicle assessment during the menstrual cycle. The wash-out period for any hormonal treatment is at least 3 menstrual cycles before dosing.
  • Has received an investigational product or been treated with an investigational device within 90 days prior to first drug administration and will not start any other investigational product or device study within 90 days after last study drug administration.
  • Known or suspected intolerance or hypersensitivity to the investigational product, any closely related compound, or any of the stated ingredients.
  • History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc).
  • Has donated or lost 400 mL blood or more within the last 16 weeks preceding the first day of dosing.
  • Has a mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study requirements.
  • An inability to follow a standardised diet and meal schedule or inability to fast, as required during the study.
  • Prior screen failure (where the cause of the screen failure is not deemed to be temporary), randomisation, participation, or enrolment in this study. Subjects who initially failed due to temporary non-medically significant issues are eligible for rescreening once the cause has resolved.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Naturally (spontaneously) post-menopausal women or women with bilateral oophorectomy/bilateral salpingo-oophorectomy (Parts I and II) or premenopausal women (Part III).
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Janne Komi, M.D. +358403108020 janne.komi@forendo.com
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03709420
Other Study ID Numbers  ICMJE 40-533-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Forendo Pharma Ltd
Study Sponsor  ICMJE Forendo Pharma Ltd
Collaborators  ICMJE Richmond Pharmacology Limited
Investigators  ICMJE
Principal Investigator: Ulrike Lorch, M.D. Richmond Pharmacology Limited
PRS Account Forendo Pharma Ltd
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP